Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly Taxotere plus Xeloda for first-line treatment of advanced gastric cancer
2005-002484-87Phase 2Completed
- Sponsor
- Raija Ristamäki
- Start
- Jun 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and capecitabine in gastric adenocarcinoma, sponsored by Raija Ristamäki. Primary endpoint: Change in quality of life (EORTC QLQ-C30). Started Jun 2005; status: completed.
02
Drugs
docetaxelcapecitabine
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on 2005-002484-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002484-87.